PDF herunterladen
Semin Thromb Hemost 2016; 42(04): 445-454
DOI: 10.1055/s-0036-1571343
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Newly-Recognized Roles of Factor XIII in Thrombosis

James R. Byrnes
1   Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
,
Alisa S. Wolberg
1   Department of Pathology and Laboratory Medicine, McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. April 2016 (online)

    Lizenzen und Reprints

Abstract

Arterial and venous thromboses are major contributors to coagulation-associated morbidity and mortality. Greater understanding of mechanisms leading to thrombus formation and stability is expected to lead to improved treatment strategies. Factor XIII (FXIII) is a transglutaminase found in plasma and platelets. During thrombosis, activated FXIII cross-links fibrin and promotes thrombus stability. Recent studies have provided new information about FXIII activity during coagulation and its effects on clot composition and function. These findings reveal newly-recognized roles for FXIII in thrombosis. Herein, we review published literature on FXIII biology and effects on fibrin structure and stability, epidemiologic data associating FXIII with thrombosis, and evidence from animal models indicating FXIII has an essential role in determining thrombus stability, composition, and size.

Keywords

factor XIII - myocardial infarction - venous thromboembolism - stroke - fibrinogen
 

  • References

  • 1 Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg 2012; 114 (2) 275-285
    CrossrefPubMedGoogle Scholar
  • 2 Wolberg AS, Rosendaal FR, Weitz JI , et al. Venous thrombosis. Nature Reviews Disease Primers 2015; 1: 15006
    PubMedGoogle Scholar
  • 3 Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91 (3) 931-972
    CrossrefPubMedGoogle Scholar
  • 4 Fickenscher K, Aab A, Stüber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991; 65 (5) 535-540
    PubMedGoogle Scholar
  • 5 Schroeder V, Kohler HP. Factor XIII: structure and function. Semin Thromb Hemost 2016; 42 (4) 422-428
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 6 Greenberg CS, Shuman MA. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem 1982; 257 (11) 6096-6101
    PubMedGoogle Scholar
  • 7 Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing γ chains. Biochemistry 1996; 35 (32) 10448-10453
    CrossrefPubMedGoogle Scholar
  • 8 Moaddel M, Farrell DH, Daugherty MA, Fried MG. Interactions of human fibrinogens with factor XIII: roles of calcium and the γ' peptide. Biochemistry 2000; 39 (22) 6698-6705
    CrossrefPubMedGoogle Scholar
  • 9 Gersh KL, Lord ST. An investigation of factor XIII binding to recombinant γ'/γ' and γ/γ' fibrinogen. Blood 2006; 108 (11) : Abstract 1705
    PubMedGoogle Scholar
  • 10 Credo RB, Curtis CG, Lorand L. α-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects. Biochemistry 1981; 20 (13) 3770-3778
    CrossrefPubMedGoogle Scholar
  • 11 Smith KA, Adamson PJ, Pease RJ , et al. Interactions between factor XIII and the alphaC region of fibrinogen. Blood 2011; 117 (12) 3460-3468
    CrossrefPubMedGoogle Scholar
  • 12 Aleman MM, Byrnes JR, Wang JG , et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014; 124 (8) 3590-3600
    CrossrefPubMedGoogle Scholar
  • 13 Souri M, Osaki T, Ichinose A. The non-catalytic B subunit of coagulation factor XIII accelerates fibrin cross-linking. J Biol Chem 2015; 290 (19) 12027-12039
    CrossrefPubMedGoogle Scholar
  • 14 Katona E E, Ajzner E, Tóth K, Kárpáti L, Muszbek L. Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates. J Immunol Methods 2001; 258 (1–2) 127-135
    CrossrefPubMedGoogle Scholar
  • 15 Elgheznawy A, Shi L, Hu J , et al. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res 2015; 117 (2) 157-165
    CrossrefPubMedGoogle Scholar
  • 16 Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood 2014; 124 (26) 3982-3990
    CrossrefPubMedGoogle Scholar
  • 17 Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry 1974; 13 (4) 750-756
    CrossrefPubMedGoogle Scholar
  • 18 Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb Haemost 2007; 97 (6) 890-898
    PubMedGoogle Scholar
  • 19 Hornyak TJ, Shafer JA. Role of calcium ion in the generation of factor XIII activity. Biochemistry 1991; 30 (25) 6175-6182
    CrossrefPubMedGoogle Scholar
  • 20 Credo RB, Curtis CG, Lorand L. Ca2+-related regulatory function of fibrinogen. Proc Natl Acad Sci U S A 1978; 75 (9) 4234-4237
    CrossrefPubMedGoogle Scholar
  • 21 Hornyak TJ, Shafer JA. Interactions of factor XIII with fibrin as substrate and cofactor. Biochemistry 1992; 31 (2) 423-429
    CrossrefPubMedGoogle Scholar
  • 22 Ando Y, Imamura S, Yamagata Y , et al. Platelet factor XIII is activated by calpain. Biochem Biophys Res Commun 1987; 144 (1) 484-490
    CrossrefPubMedGoogle Scholar
  • 23 Muszbek L, Polgár J, Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993; 69 (3) 282-285
    PubMedGoogle Scholar
  • 24 Smith KA, Pease RJ, Avery CA , et al. The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. Blood 2013; 121 (11) 2117-2126
    CrossrefPubMedGoogle Scholar
  • 25 Ortner E, Schroeder V, Walser R, Zerbe O, Kohler HP. Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood 2010; 115 (24) 5089-5096
    CrossrefPubMedGoogle Scholar
  • 26 Finlayson JS, Aronson DL. Crosslinking of rabbit fibrin in vivo. Thromb Diath Haemorrh 1974; 31 (3) 435-438
    PubMedGoogle Scholar
  • 27 Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation 2000; 102 (10) 1151-1157
    CrossrefPubMedGoogle Scholar
  • 28 Bagoly Z, Haramura G, Muszbek L. Down-regulation of activated factor XIII by polymorphonuclear granulocyte proteases within fibrin clot. Thromb Haemost 2007; 98 (2) 359-367
    PubMedGoogle Scholar
  • 29 Hedner U, Johansson L, Nilsson IM. Effects of porcine plasmin on the coagulation and fibrinolytic systems in humans. Blood 1978; 51 (1) 157-164
    PubMedGoogle Scholar
  • 30 Rider DM, McDonagh J. Resistance of factor XIII to degradation or activation by plasmin. Biochim Biophys Acta 1981; 675 (2) 171-177
    CrossrefPubMedGoogle Scholar
  • 31 Hur WS, Mazinani N, Lu XJ , et al. Coagulation factor XIIIa is inactivated by plasmin. Blood 2015; 126 (20) 2329-2337
    CrossrefPubMedGoogle Scholar
  • 32 Doiphode PG, Malovichko MV, Mouapi KN, Maurer MC. Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. Anal Biochem 2014; 457: 74-84
    CrossrefPubMedGoogle Scholar
  • 33 Cleary DB, Maurer MC. Characterizing the specificity of activated Factor XIII for glutamine-containing substrate peptides. Biochim Biophys Acta 2006; 1764 (7) 1207-1217
    CrossrefPubMedGoogle Scholar
  • 34 Nikolajsen CL, Dyrlund TF, Poulsen ET, Enghild JJ, Scavenius C. Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot. J Biol Chem 2014; 289 (10) 6526-6534
    CrossrefPubMedGoogle Scholar
  • 35 Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77 (5) 2813-2826
    CrossrefPubMedGoogle Scholar
  • 36 Collet JP, Moen JL, Veklich YI , et al. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. Blood 2005; 106 (12) 3824-3830
    CrossrefPubMedGoogle Scholar
  • 37 Standeven KF, Carter AM, Grant PJ , et al. Functional analysis of fibrin γ-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood 2007; 110 (3) 902-907
    CrossrefPubMedGoogle Scholar
  • 38 Hethershaw EL, Cilia La Corte AL, Duval C , et al. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12 (2) 197-205
    CrossrefPubMedGoogle Scholar
  • 39 Byrnes JR, Duval C, Wang Y , et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015; 126 (16) 1940-1948
    CrossrefPubMedGoogle Scholar
  • 40 Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014; 12 (10) 1687-1696
    CrossrefPubMedGoogle Scholar
  • 41 van Giezen JJ, Minkema J, Bouma BN, Jansen JW. Cross-linking of α 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences. Blood Coagul Fibrinolysis 1993; 4 (6) 869-875
    CrossrefPubMedGoogle Scholar
  • 42 Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through α2-antiplasmin cross-linking. Blood 2011; 117 (23) 6371-6374
    CrossrefPubMedGoogle Scholar
  • 43 Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998; 273 (42) 27220-27224
    CrossrefPubMedGoogle Scholar
  • 44 Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur J Biochem 1993; 214 (1) 141-146
    CrossrefPubMedGoogle Scholar
  • 45 Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of α2-antiplasmin to fibrin. Thromb Haemost 1992; 68 (3) 315-320
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 46 Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual fibrin fiber in a clot. Proc Natl Acad Sci U S A 2005; 102 (26) 9133-9137
    CrossrefPubMedGoogle Scholar
  • 47 Liu W, Jawerth LM, Sparks EA , et al. Fibrin fibers have extraordinary extensibility and elasticity. Science 2006; 313 (5787) 634
    CrossrefPubMedGoogle Scholar
  • 48 Houser JR, Hudson NE, Ping L , et al. Evidence that αC region is origin of low modulus, high extensibility, and strain stiffening in fibrin fibers. Biophys J 2010; 99 (9) 3038-3047
    CrossrefPubMedGoogle Scholar
  • 49 Glover CJ, McIntire LV, Brown III CH, Natelson EA. Rheological properties of fibrin clots. Effects of fibrinogen concentration, Factor XIII deficiency, and Factor XIII inhibition. J Lab Clin Med 1975; 86 (4) 644-656
    PubMedGoogle Scholar
  • 50 Ryan EA, Mockros LF, Stern AM, Lorand L. Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. Biophys J 1999; 77 (5) 2827-2836
    CrossrefPubMedGoogle Scholar
  • 51 Helms CC, Ariëns RA, Uitte de Willige S, Standeven KF, Guthold M. α-α Cross-links increase fibrin fiber elasticity and stiffness. Biophys J 2012; 102 (1) 168-175
    CrossrefPubMedGoogle Scholar
  • 52 Duval C, Allan P, Connell SD, Ridger VC, Philippou H, Ariëns RA. Roles of fibrin α- and γ-chain specific cross-linking by FXIIIa in fibrin structure and function. Thromb Haemost 2014; 111 (5) 842-850
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 53 Cohen I, Gerrard JM, White JG. Ultrastructure of clots during isometric contraction. J Cell Biol 1982; 93 (3) 775-787
    CrossrefPubMedGoogle Scholar
  • 54 Endo Y, Takahashi K, Mamiya S, Satoh M, Matsuda M. Factor XIII deficiency associated with Klippel-Weber disease, platelet dysfunction and cryofibrinogenemia. Acta Haematol 1983; 69 (6) 398-403
    CrossrefPubMedGoogle Scholar
  • 55 Kasahara K, Souri M, Kaneda M, Miki T, Yamamoto N, Ichinose A. Impaired clot retraction in factor XIII A subunit-deficient mice. Blood 2010; 115 (6) 1277-1279
    CrossrefPubMedGoogle Scholar
  • 56 Hanna M. Congenital deficiency of factor 13: report of a family from Newfoundland with associated mild deficiency of factor XII. Pediatrics 1970; 46 (4) 611-619
    PubMedGoogle Scholar
  • 57 Rao KM, Newcomb TF. Clot retraction in a factor XIII free system. Scand J Haematol 1980; 24 (2) 142-148
    PubMedGoogle Scholar
  • 58 Jelenska M, Kopeć M, Breddin K. On the retraction of collagen and fibrin induced by normal, defective and modified platelets. Haemostasis 1985; 15 (3) 169-175
    PubMedGoogle Scholar
  • 59 Aleman MM, Holle LA, Stember KG, Devette CI, Monroe DM, Wolberg AS. Cystamine preparations exhibit anticoagulant activity. PLoS ONE 2015; 10 (4) e0124448
    CrossrefPubMedGoogle Scholar
  • 60 Cines DB, Lebedeva T, Nagaswami C , et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014; 123 (10) 1596-1603
    CrossrefPubMedGoogle Scholar
  • 61 Hasegawa G, Suwa M, Ichikawa Y , et al. A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 2003; 373 (Pt 3): 793-803
    CrossrefPubMedGoogle Scholar
  • 62 Lahav J, Karniel E, Bagoly Z, Sheptovitsky V, Dardik R, Inbal A. Coagulation factor XIII serves as protein disulfide isomerase. Thromb Haemost 2009; 101 (5) 840-844
    PubMedGoogle Scholar
  • 63 Furie B, Flaumenhaft R. Thiol isomerases in thrombus formation. Circ Res 2014; 114 (7) 1162-1173
    CrossrefPubMedGoogle Scholar
  • 64 Chiu J, Passam F, Butera D, Hogg PJ. Protein disulfide isomerase in thrombosis. Semin Thromb Hemost 2015; 41 (7) 765-773
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008; 6 (3) 190-205
    CrossrefPubMedGoogle Scholar
  • 66 Bereczky Z, Muszbek L. Factor XIII and venous thromboembolism. Semin Thromb Hemost 2011; 37 (3) 305-314
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 67 Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res 2012; 129 (3) 382-387
    CrossrefPubMedGoogle Scholar
  • 68 Muszbek L. Deficiency causing mutations and common polymorphisms in the factor XIII-A gene. Thromb Haemost 2000; 84 (4) 524-527
    PubMedGoogle Scholar
  • 69 Wartiovaara U, Mikkola H, Szôke G , et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84 (4) 595-600
    PubMedGoogle Scholar
  • 70 Balogh I, Szôke G, Kárpáti L , et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96 (7) 2479-2486
    PubMedGoogle Scholar
  • 71 Ariëns RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96 (3) 988-995
    CrossrefPubMedGoogle Scholar
  • 72 Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93 (3) 906-908
    PubMedGoogle Scholar
  • 73 Franco RF, Reitsma PH, Lourenço D , et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81 (5) 676-679
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 74 Margaglione M, Bossone A, Brancaccio V, Ciampa A, Di Minno G. Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis. Thromb Haemost 2000; 84 (6) 1118-1119
    PubMedGoogle Scholar
  • 75 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79 (1) 8-13
    PubMedGoogle Scholar
  • 76 Aleksic N, Ahn C, Wang YW , et al. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2002; 22 (2) 348-352
    CrossrefPubMedGoogle Scholar
  • 77 Reiner AP, Heckbert SR, Vos HL , et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003; 102 (1) 25-30
    CrossrefPubMedGoogle Scholar
  • 78 Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107 (8) 1117-1122
    CrossrefPubMedGoogle Scholar
  • 79 Vokó Z, Bereczky Z, Katona E, Adány R, Muszbek L. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost 2007; 97 (3) 458-463
    PubMedGoogle Scholar
  • 80 Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol 2006; 164 (2) 101-109
    CrossrefPubMedGoogle Scholar
  • 81 Van Hylckama Vlieg A, Komanasin N, Ariëns RA , et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119 (1) 169-175
    CrossrefPubMedGoogle Scholar
  • 82 Vossen CY, Rosendaal FR. The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J Thromb Haemost 2005; 3 (5) 1102-1103
    CrossrefPubMedGoogle Scholar
  • 83 Boekholdt SM, Sandhu MS, Wareham NJ, Luben R, Reitsma PH, Khaw KT. Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost 2006; 4 (10) 2204-2209
    CrossrefPubMedGoogle Scholar
  • 84 Bereczky Z, Balogh E, Katona E , et al. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 2007; 120 (4) 567-573
    CrossrefPubMedGoogle Scholar
  • 85 Lim BC, Ariëns RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361 (9367) 1424-1431
    CrossrefPubMedGoogle Scholar
  • 86 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21 (3) 131-142
    CrossrefPubMedGoogle Scholar
  • 87 Pruissen DM, Slooter AJ, Rosendaal FR, van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008; 111 (3) 1282-1286
    CrossrefPubMedGoogle Scholar
  • 88 Siegerink B, Maino A, Algra A, Rosendaal FR. Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. J Thromb Haemost 2015; 13 (9) 1568-1575
    CrossrefPubMedGoogle Scholar
  • 89 Landau MB, Renni MS, Zalis MG, Spector N, Gadelha T. Coagulation factor XIII Tyr204Phe gene variant and the risk of ischemic stroke. J Thromb Haemost 2013; 11 (7) 1426-1427
    CrossrefPubMedGoogle Scholar
  • 90 Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg A, Rosendaal FR, Ariëns RA. A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005; 3 (11) 2487-2496
    CrossrefPubMedGoogle Scholar
  • 91 Pourgheysari B, Drees F, Hashemzadeh-Chaleshtori M. Factor XIIIA-V34L and factor XIIIB-H95R in venous thromboembolism in central Iran: protective and neutral. Blood Coagul Fibrinolysis 2014; 25 (5) 439-443
    CrossrefPubMedGoogle Scholar
  • 92 Mezei ZA, Bereczky Z, Katona É , et al. Factor XIII B subunit polymorphisms and the risk of coronary artery disease. Int J Mol Sci 2015; 16 (1) 1143-1159
    CrossrefPubMedGoogle Scholar
  • 93 Iwata H, Kitano T, Umetsu K , et al. Distinct C-terminus of the B subunit of factor XIII in a population-associated major phenotype: the first case of complete allele-specific alternative splicing products in the coagulation and fibrinolytic systems. J Thromb Haemost 2009; 7 (7) 1084-1091
    CrossrefPubMedGoogle Scholar
  • 94 Bereczky Z, Balogh E, Katona E, Czuriga I, Edes I, Muszbek L. Elevated factor XIII level and the risk of myocardial infarction in women. Haematologica 2007; 92 (2) 287-288
    CrossrefPubMedGoogle Scholar
  • 95 Shemirani AH, Szomják E, Csiki Z, Katona E, Bereczky Z, Muszbek L. Elevated factor XIII level and the risk of peripheral artery disease. Haematologica 2008; 93 (9) 1430-1432
    CrossrefPubMedGoogle Scholar
  • 96 Shemirani AH, Antalfi B, Pongrácz E, Mezei ZA, Bereczky Z, Csiki Z. Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke. Blood Coagul Fibrinolysis 2014; 25 (4) 364-368
    CrossrefPubMedGoogle Scholar
  • 97 Mansfield MW, Kohler HP, Ariëns RA, McCormack LJ, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care 2000; 23 (5) 703-705
    CrossrefPubMedGoogle Scholar
  • 98 Gemmati D, Zeri G, Orioli E , et al. Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker?. Thromb Haemost 2015; 114 (1) 123-132
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 99 Nahrendorf M, Hu K, Frantz S , et al. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113 (9) 1196-1202
    CrossrefPubMedGoogle Scholar
  • 100 Nahrendorf M, Aikawa E, Figueiredo JL , et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur Heart J 2008; 29 (4) 445-454
    CrossrefPubMedGoogle Scholar
  • 101 Leidy EM, Stern AM, Friedman PA, Bush LR. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis. Thromb Res 1990; 59 (1) 15-26
    CrossrefPubMedGoogle Scholar
  • 102 Shebuski RJ, Sitko GR, Claremon DA, Baldwin JJ, Remy DC, Stern AM. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator. Blood 1990; 75 (7) 1455-1459
    PubMedGoogle Scholar
  • 103 Jaffer FA, Tung CH, Wykrzykowska JJ , et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation 2004; 110 (2) 170-176
    CrossrefPubMedGoogle Scholar
  • 104 Gosk-Bierska I, McBane RD, Wu Y , et al. Platelet factor XIII gene expression and embolic propensity in atrial fibrillation. Thromb Haemost 2011; 106 (1) 75-82
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 105 Ni H, Yuen PS, Papalia JM , et al. Plasma fibronectin promotes thrombus growth and stability in injured arterioles. Proc Natl Acad Sci U S A 2003; 100 (5) 2415-2419
    CrossrefPubMedGoogle Scholar
  • 106 Cho J, Mosher DF. Impact of fibronectin assembly on platelet thrombus formation in response to type I collagen and von Willebrand factor. Blood 2006; 108 (7) 2229-2236
    CrossrefPubMedGoogle Scholar
  • 107 Wang Y, Reheman A, Spring CM , et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 2014; 124 (10) 4281-4293
    CrossrefPubMedGoogle Scholar
  • 108 Shaya SA, Saldanha LJ, Vaezzadeh N, Zhou J, Ni R, Gross PL. Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. J Thromb Haemost 2016; 14 (1) 143-152
    CrossrefPubMedGoogle Scholar
  • 109 Laki K, Lóránd L. On the solubility of fibrin clots. Science 1948; 108 (2802) 280
    CrossrefPubMedGoogle Scholar
  • 110 Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler Thromb Vasc Biol 2011; 31 (3) 494-499
    CrossrefPubMedGoogle Scholar